Neoantigen Targeted Therapies Market Report 2026

The neoantigen targeted therapies market size has grown exponentially in recent years. It will grow from $4.71 billion in 2025 to $6.39 billion in 2026 at a compound annual growth rate (CAGR) of 35.8%. The growth in the historic period can be attributed to limited immunotherapy options, slow cancer vaccine development, early-stage genomic sequencing usage, restricted clinical trial availability, traditional oncology treatment dependency.

The neoantigen targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $21.52 billion in 2030 at a compound annual growth rate (CAGR) of 35.5%. The growth in the forecast period can be attributed to rapid growth of personalized cancer therapies, increased investment in genomic sequencing, expanding clinical research collaborations, rising adoption of combination immunotherapies, growing demand for precision oncology solutions. Major trends in the forecast period include increasing adoption of personalized cancer vaccines, expansion of targeted immunotherapy research pipelines, rising clinical trials for neoantigen-based combination therapies, growing demand for early genetic profiling in oncology, surge in development of til-based therapeutic approaches.

The increasing adoption of precision oncology is expected to drive the growth of the neoantigen-targeted therapies market in the coming years. Precision oncology is a cancer treatment approach that uses detailed genetic and molecular information about a patient’s tumor to guide the selection of targeted therapies. In this context, neoantigen-targeted therapies are utilized by applying advanced genomic analyses to identify unique neoantigens expressed by an individual’s cancer cells. This approach allows treatments to be tailored to the specific genetic makeup of each patient’s tumor, providing more personalized and effective therapeutic options. For example, in March 2024, the Precision Oncology Clinical Trials & Statistics 2024 report published by Novotech, an Australia-based full-service clinical contract research organization, highlighted that by November 2023, twelve treatments had received FDA approval for specific biomarker-selected indications, six of which were included in NCCN guidelines. By the end of the year, 43% of the 217 FDA-approved oncology therapies were classified as precision oncology, with 78 therapies featuring DNA or NGS-detectable biomarkers, underscoring the rising importance of biomarker-driven cancer treatments. Consequently, the expansion of precision oncology is propelling the growth of the neoantigen-targeted therapies market.

Leading companies in the neoantigen-targeted therapies market are increasingly forming strategic partnerships to develop personalized neoantigen vaccines and monoclonal antibody drugs, addressing limitations of current immunotherapy approaches in treating solid tumors. Strategic partnerships involve companies combining resources and expertise for mutual benefit and innovation. For instance, in April 2023, Moderna, Inc., a US-based pharmaceutical and biotechnology company, partnered with Merck & Co., Inc., a US-based pharmaceutical company, to launch mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT). This therapy is designed to produce a customized antitumor immune response based on the unique mutational profile of a patient’s tumor. mRNA-4157 (V940) encodes up to 34 neoantigens to stimulate T cell responses, enhancing the immune system’s ability to target and destroy tumor cells when combined with Merck’s immunotherapy KEYTRUDA, aiming to improve recurrence-free survival in patients with high-risk resected melanoma.

In January 2023, AstraZeneca plc, a UK-based pharmaceutical company, acquired Neogene Therapeutics Inc. for $200 million. The acquisition aims to strengthen AstraZeneca’s oncology portfolio by advancing the development of transformative T-cell receptor (TCR) therapies targeting neoantigens in solid tumors. Neogene’s expertise in next-generation TCR-T therapies is expected to complement AstraZeneca’s existing capabilities in oncology, facilitating further progress in cancer treatment innovations. Neogene Therapeutics Inc., based in the US, specializes in neoantigen-targeted therapies.

Major companies operating in the neoantigen targeted therapies market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Kite Pharma Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

North America was the largest region in the neoantigen targeted therapies market in 2025. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neoantigen targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on biopharmaceutical raw materials, sequencing equipment, and specialized laboratory technologies have increased operational and production costs for neoantigen-targeted therapies. These impacts are most significant in regions dependent on imported genetic testing tools and biologics, particularly in Asia-Pacific and Latin America. While tariffs elevate development expenses, they also encourage localized manufacturing of biologics and genomic analysis platforms, potentially driving innovation and reducing long-term dependency on foreign suppliers.

The neoantigen targeted therapies market research report is one of a series of new reports that provides neoantigen targeted therapies market statistics, including neoantigen targeted therapies industry global market size, regional shares, competitors with a neoantigen targeted therapies market share, detailed neoantigen targeted therapies market segments, market trends and opportunities, and any further data you may need to thrive in the neoantigen targeted therapies industry. This neoantigen targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neoantigen-targeted therapies are a form of precision medicine that focus on neoantigens found in cancer cells. Neoantigens are unique antigens arising from genetic mutations or alterations in cancer cells. These therapies aim to harness the immune system to specifically recognize and attack cancer cells by targeting these neoantigens.

The main types of neoantigen-targeted therapies are monotherapy and combination therapy. Monotherapy refers to a treatment approach using a single drug or therapy to address a disease. Immunotherapy types include DNA- or RNA-based vaccines, protein-based vaccines, dendritic cell vaccines, and TIL-based therapies, targeting cancers such as colorectal cancer, renal cell carcinoma, non-small cell lung cancer, bone cancer, and gynecological cancers. Routes of administration include intradermal, intravenous, and subcutaneous, and these therapies are applied in medical research institutions, hospitals, clinics, and other healthcare settings.

The neoantigen targeted therapies market consists of revenues earned by entities by providing services such as the identification and characterization of neoantigens in individual patients, the selection and administration of the appropriate therapy, and the monitoring of patients' responses. The market value includes the value of related goods sold by the service provider or included within the service offering. Neoantigen targeted therapies also include the sale of neoantigen-based cancer vaccines and genetically modified T cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.